Exenatide BID Observational Study (ExOS): Results for primary and secondary endpoints of a prospective research study to evaluate the clinical effectiveness of exenatide BID use in patients with type 2 diabetes in a real-world setting

Current Medical Research and Opinion

Volumn 27, Issue 12, 2011, Pages 2335-2342

  Bergenstal, Richard M ^a   Garrison Jr , Louis P ^b   Miller, Lesley Ann ^c   Hou, Likun ^d   Blickensderfer, Amy ^e   Zagar, Anthony ^c   Stanley, Shelley ^d   Bhargava, Anuj ^f   Wade, Rolin ^g   Herman, William H ^h  

^a INTERNATIONAL DIABETES CENTER   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c ELI LILLY AND COMPANY   (United States)

^d HEALTHCORE INC   (United States)

^e AMYLIN PHARMACEUTICALS INC   (United States)

^f MERCY MEDICAL CENTER   (United States)

^g CERNER CORPORATION   (United States)

^h UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Body weight; Diabetes mellitus; Exenatide; HbA1c; Observational

Indexed keywords

EXENDIN 4; HEMOGLOBIN A1C; LIPID;

ARTICLE; BODY MASS; BODY WEIGHT; CLINICAL EFFECTIVENESS; FAMILY HISTORY; FOLLOW UP; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; QUALITY OF LIFE; TREATMENT OUTCOME;

AGED; BIOLOGICAL MARKERS; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; LIPIDS; MALE; MIDDLE AGED; PEPTIDES; PROSPECTIVE STUDIES; QUALITY OF LIFE; TIME FACTORS; VENOMS;

EID: 81855221189     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.628305     Document Type: Article

References (27)

1. Nielsen LL, Young AA, Parkes DG. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept 2004;117:77-88
2. Edwards CM, Stanley SA, Davis R, et al. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 2001;281:E155-61
3. Fineman MS, Bicsak TA, Shen LZ, et al. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 2003;26:2370-7
4. Kolterman OG, Buse JB, Fineman MS, et al. Synthetic exendin-4(exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003;88:3082-9
5. Nielsen LL, Baron AD. Pharmacology of exenatide (synthetic exendin-4) for the treatment of type 2 diabetes. Curr Opin Investig Drugs 2003;4:401-5
6. Parkes DG, Pittner R, Jodka C, et al. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro. Metabolism 2001;50:583-9
7. Young AA, Gedulin BR, Bhavsar S, et al. Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes 1999;48:1026-34
8. Buse JB, Henry RR, Han J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004;27:2628-35
9. DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28:1092-100
10. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28:1083-91
11. Klonoff DC, Buse JB, Nielsen LL, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008;24:275-86
12. Brixner DI, McAdam-Marx C, Ye X, et al. Six-month outcomes on A1C and cardiovascular risk factors in patients with type 2 diabetes treated with exenatide in an ambulatory care setting. Diabetes Obes Metab 2009;11:1122-30
13. Brixner DI, McAdam-Marx C, Ye X, et al. Real-world six month outcomes of patients initiating exenatide in a primary care electronic medical record database [ISPOR abstract DB1]. Value Health 2008;11(Suppl):A17
14. Brixner DI, McAdam-Marx C, Ye X, et al. 18 month A1C and weight outcomes of exenatide therapy in patients with type-2 diabetes in a real-world study [ISPOR abstract PDB6]. Value Health 2009;12(Suppl):A97
15. Fabunmi R, McAdam-Marx C, Ye X, et al. Blood pressure outcomes after 6 months of exenatide treatment in patients with type 2 diabetes in a real world study [ADA abstract 470-P]. Diabetes 2009;58(Suppl 1):A125
16. McAdam-Marx C, Brixner DI, Ye X, et al. A1C and weight outcomes following 6 months of analog basil insulin in insulin-naïve patients with type 2 diabetes in an ambulatory care setting [ISPOR abstract PDB2]. Value Health 2009;12(Suppl):A97
17. Wade R, Quimbo R, Fabunmi R, et al. Utilization patterns and hypoglycemia in patients with type 2 diabetes on concomitant exenatide and long-acting insulin therapy [ISPOR abstract PDB15]. Value Health 2009;12(Suppl):A99
18. Fabunmi R, Nielsen LL, Quimbo R, et al. Patient characteristics, drug adherence patterns, and hypoglycemia costs for patients with type 2 diabetes mellitus newly initiated on exenatide or insulin glargine. Curr Med Res Opin 2009;25:777-86
19. Bergenstal RM, Garrison LP, Wintle M, et al. Exenatide bid observational study (ExOS): baseline population characteristics of a prospective research study to evaluate the clinical effectiveness of exenatide bid use in patients with type 2 diabetes in a real-world setting. Curr Med Res Opin 2011;27:531-40
20. American Diabetes Association. Standards of Medical Care in Diabetes - 2007. Diabetes Care 2007;30(Suppl 1):S4-41
21. Washington MC, Raboin SJ, Thompson W, et al. Exenatide reduces food intake and activates the enteric nervous system of the gastrointestinal tract and the dorsal vagal complex of the hindbrain in the rat by a GLP-1 receptor. Brain Res 2010;16:124-33
22. Joy SV, Rodgers PT, Scates AC. New drug developments: incretin mimetics as emerging treatments for type 2 diabetes. Ann Pharmacother 2005;39:110-18
23. Edwards CM, Stanley SA, Davis R, et al. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 2001;281:E155-61
24. Exenatide (Byetta) injection prescribing information. Amylin Pharmaceuticals, Inc., 2005
25. Drucker DJ. The biology of incretin hormones. Cell Metab 2006;3:153-65
26. Kolterman OG, Kim DD, Shen L, et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm 2005;62:173-81
27. Yeaw J, Benner JS, Walt JG, et al. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm 2009;15:728-40